InflaRx NV IFRX

Healthcare Biotechnology

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

NDAQ:IFRX - Post by User

InflaRx NV

<< Previous

Bullboard Posts

Next >>

Post by Sokratesaes86on Jan 09, 2022 10:40am

139 Views

Post# 34297439

Ab very very BiG Market

Inflarx sepsis drug. Cost in the US alone. Values from then are now much higher. In 2011, sepsis topped the list of the most cost-intensive conditions in the United States, with total hospital costs of $ 22.2 billion annually

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price